📢 Residents & Fellows: Help shape the future of immunotherapy education! Participate in our 5-min anonymous survey on #irAE experiences.🩺
Program directors and faculty—please share with your trainees!
Complete the survey:🔗 shorturl.at/GMNMY#ASPIRECOP#OncMedEd
🚨irAE aficianados! Help shape @ASCO guidelines in part 1 of open comment on the next iteration of ASCO's irAE guidelines. Open for comment until Wed 6/10 ✍️
Part 1: 🫁👁️👄
Link to comment here 👇
asco1.qualtrics.com/jfe/form…
🔥 Exciting sessions to watch out for at #ASCO26!
🛡️ High-risk patients deserve immunotherapy too. How do we get them there safely?
📋 Advancing ICI Therapy in High-Risk Populations
🗓️ Mon Jun 1
🕖4:45–6:00 PM CT
📍 Room E450a
#irAEs#immunotherapy
Big morning for #irAE research at #ASCO26
📍Hall A is full of it!
A few we're watching: ICI rechallenge after irAE (#11127), CAR-T thyroid toxicity (#11148), and pan-cancer genomic drivers of irAEs (#11132). Go see them!
🔥 Exciting sessions to watch out for at #ASCO26!
⚔️ Bispecifics are powerful — and so are their toxicities. Grab the management playbook.
📋 Management of Bispecific Antibody Toxicities
🗓️ Sun May 31
🕞 11:30 AM–12:45 PM CT
📍 Room E450a
#irAEs
🫁 Severe checkpoint inhibitor pneumonitis on steroids alone? Fresh phase 2 data on add-on ruxolitinib.
🎙️ Dr. Yan Xu · Peking Union Medical College Hospital
🗓️ Sun May 31 · 9:06 AM CT
📍 Room S403
#ASCO26#irAEs#LungCancer
Using all our resources for irAE: @afreenshariffmd identifies areas that AI can accelerate care for irAEs with agentic PRO and follow up @ASPIRE_CoP#ASCO26
Building an IOTOX service line @kreynoldsMD@ASPIRE_CoP#ASCO26
➡️align with institutional priorities
➡️name your program
➡️meet regularly and invite broadly
➡️connect to the scientific community
➡️start somewhere, a pilot project etc
➡️partner with patients
@afreenshariffmd